Effect of albiglutide on cardiovascular outcomes in older adults: A post hoc analysis of a randomized controlled trial

Overview of attention for article published in Diabetes, Obesity & Metabolism, February 2024

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (91st percentile)
High Attention Score compared to outputs of the same age and source (91st percentile)

Mentioned by

news: 2 news outlets
twitter: 1 X user

peer_reviews: 1 peer review site

Readers on

mendeley: 6 Mendeley

Summary News X Peer reviews

So far, Altmetric has seen 2 news stories from 2 outlets.

Albiglutide Therapy Reduces Cardiovascular Events in Type 2 Diabetes

Rheumatology Advisor, 27 Feb 2024

Albiglutide, a long-acting glucagon-like peptide-1 receptor agonist, reduces the risk of cardiovascular events among older…

Albiglutide Therapy Reduces Cardiovascular Events in Type 2 Diabetes

Endocrinology Advisor, 26 Feb 2024

Albiglutide, a long-acting glucagon-like peptide-1 receptor agonist, reduces the risk of cardiovascular events among older…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity.